In addition, the Phase II clinical trial of tazemetostat combined with R-CHOP (NCT02889523) and PD-L1 antibody atezolizumab (NCT02220842) in the treatment of DLBCL are in progress. Here, CD274 is linked to diffuse large B-cell lymphoma.